Consideration of dornase alfa for the treatment of severe COVID-19 acute respiratory distress syndrome

We propose a likely contribution to severe COVID-19 morbidity by extracellular DNA in neutrophil extracellular traps (NETs). Dornase alfa degrades extracellular DNA to reduce mucus rigidity and accumulation, and was associated with respiratory improvement in a first patient. Dornase alfa should be c...

Full description

Saved in:
Bibliographic Details
Published in:New microbes and new infections 2020-05, Vol.35, p.100689-100689, Article 100689
Main Authors: Earhart, A.P., Holliday, Z.M., Hofmann, H.V., Schrum, A.G.
Format: Article
Language:English
Subjects:
acute respiratory distress syndrome
COVID-19
DNAse 1
dornase alfa
Letter to the Editor
Neutrophil extracellular trap
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We propose a likely contribution to severe COVID-19 morbidity by extracellular DNA in neutrophil extracellular traps (NETs). Dornase alfa degrades extracellular DNA to reduce mucus rigidity and accumulation, and was associated with respiratory improvement in a first patient. Dornase alfa should be considered for clinical trials in treatment of severe COVID-19.
ISSN:2052-2975
2052-2975
DOI:10.1016/j.nmni.2020.100689